Completed PHASE1 INTERVENTIONAL 2-arm NCT00931541

AZD6088 Single Ascending Dose Study

A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral AZD6088 After Single Ascending Doses in Healthy Male and Non-Fertile Female Volunteers

Sponsor: AstraZeneca

Conditions Healthy Volunteers

Interventions AZD6088 Placebo

Updated 5 times since 2017 Last updated: Sep 9, 2009 Started: Jun 30, 2009 Completion: Aug 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00931541, this PHASE1 trial focuses on Healthy Volunteers and remains completed. Sponsored by AstraZeneca, it has been updated 5 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Jun 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca

Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• London Bridge, United Kingdom